Navigation Links
FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
Date:2/4/2011

t with a single fetus and had a history of a prior spontaneous preterm birth. Among women treated with Makena, 37 percent delivered early (before 37 weeks) as compared with 55 percent of women in the control group.  

A separate study evaluated the development of children born to mothers enrolled in the controlled trial. In this study, children ages 2.5 years to 5 years reached similar developmental targets, regardless of the mother's treatment.  The confirmatory study that is ongoing will be followed by a similar infant follow-up study, to be completed about 2018.  That study is expected to include 580-750 infants, depending on the number of study sites and mothers willing to participate.  

The most common side effects reported with Makena included pain, swelling, or itching at the injection site; hives, nausea and diarrhea. Serious adverse reactions were rare; there was a single report each of blood clot in the lungs (pulmonary embolism) and an infection at the injection site.

The FDA originally approved hydroxyprogesterone caproate under the trade name Delalutin in 1956 for use in pregnant women. The approved indications include threatened miscarriage. The original manufacturer requested the withdrawal of Delalutin from the market in 2000 for reasons unrelated to safety.

Consumers and health care professionals are encouraged to report adverse events from medications to the FDA's MedWatch program at 800-FDA-1088 or online at www.fda.gov/medwatch/how.htm.

Makena is manufactured by Baxter Pharmaceutical Solutions LLC, based in Bloomington, Ind.

For more information:

Approved Drugs: Questions and Answers

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/UCM054420  

<
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a ... its first patient in its study for ischemic ... American Stroke Association, ischemic strokes account for 87 ... enroll qualified patients in the study, entitled "Internal ... of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... and INDIANAPOLIS , March 15 ... evaluated response rates in patients with a common genetic ... TRITON-TIMI 38 study were treated with dual antiplatelet therapy ... plus aspirin and managed with percutaneous coronary intervention (PCI) ...
... March 15 At this year,s annual meeting ... 14-16 in Atlanta , Royal Philips Electronics ... simplifying cardiology patient care by highlighting a range of ... tools, intuitive information management systems, new temperature modulation therapies, ...
Cached Medicine Technology:New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 2New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 3New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 4New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 5New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 6New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 7New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 8New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 9New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 10New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 11Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 2Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 3Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 4Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 5Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 6Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 7Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 8Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 9
(Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
(Date:12/25/2014)... December 25, 2014 Each year trauma ... 2 million hospital admissions across the nation (according to ... The CDC’s National Hospital Ambulatory Medical Care Survey ... survey conducted in 2010. They estimated that there were ... resulted in a primary diagnosis of broken bone or ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... change when clocks are adjusted , , WEDNESDAY, Oct. 29 (HealthDay ... about here, and it may pose problems more serious than ... in the number of heart attacks following the semi-annual one-hour ... "This was the very first study on this topic and ...
... ORCH ), a leading worldwide provider of identity DNA ... of,2008., Total revenues were $14.9 million for the third ... of 2007. The decrease in,total revenues for the third quarter ... lower revenues in the U.K., Total U.S.-based revenues rose ...
... EPS Outlook and Announces 2009 Operating Preview, ... (Nasdaq: GTIV ), a leading provider of ... led by 17% revenue,growth and 26% operating contribution ... continued to invest in clinical innovation, quality and,productivity ...
... Get Annual Foot Check-ups, BETHESDA, Md., Oct. 30 ... and its complications every year.,However, medical care for diabetes ... according to a recent survey by the American Podiatric,Medical ... independent research firm, found that,25 percent of the 600 ...
... and Healthcare Interface Solutions Team to Integrate Innovative Web-based Referral ... , ... Atlanta, Ga. (PRWEB) October 30, ... Web-based admissions and referral automation software for hospitals and long-term ...
... by process industries and manufacturers of industrial machinery, growing demand for ... the growth in smart sensors market. Global market for Smart Sensors ... ... San Jose, CA (PRWEB) October 30, 2008 -- Sensor networks ...
Cached Medicine News:Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Health News:Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 2Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 3Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 4Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 5Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 6Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 7Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 8Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 9Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 10Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 11Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 12Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 13Health News:Gentiva Reports Third Quarter Revenue and Profit Growth 14Health News:Study Finds Preventative Diabetes Care Reduces Amputation Occurrence 2Health News:Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems 2Health News:Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems 3Health News:Global Market for Smart Sensors to Reach $7.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. 2Health News:Global Market for Smart Sensors to Reach $7.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. 3
... Comet XL is a complete EEG system ... physician's office, hospital, or medical center. Ready ... the latest high performance PC and Photic ... and monitor sizes to suit your individual ...
... system is made up of our SleepWorks software ... perfect solution to your diagnostic sleep-testing needs. It's ... of this is backed up by 24/7 support ... professionals. Not only that, you can expand your ...
Aurora is a powerful Windows-based digital PSG instrument providing complete data acquisition, recording and review capabilities in one flexible package. The Aurora offers the most feature-packed PSG...
... purpose stimulator intended for nerve and muscle ... cell to entire muscle stimulation. It can ... pulses, trains of pulses and trains of ... include computer compatibility and flexibility of synchronization ...
Medicine Products: